Personalis, Inc.
About Personalis, Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $69.6M
- Net income
- -$81.3M
- Total assets
- $334.2M
- Market cap
- $1.1B
- Gross margin
- 22.7%
- Operating margin
- -126.4%
- Net margin
- -116.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $69.6M
- Cost of revenue
- $53.9M
- Gross profit
- $15.8M
- Operating expenses
- $103.8M
- Operating income
- -$88.1M
- Income tax
- $21.0K
- Net income
- -$81.3M
- EPS (basic)
- $-0.91
- EPS (diluted)
- $-0.91
Balance sheet
- Total assets
- $334.2M
- Current assets
- $268.0M
- Total liabilities
- $73.0M
- Current liabilities
- $39.6M
- Shareholders’ equity
- $261.2M
Cash flow
- Operating cash flow
- -$74.9M
- Investing cash flow
- -$22.6M
- Financing cash flow
- $130.3M
- Net cash flow
- $32.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.1B
- EPS (diluted)
- $-0.91
- Shares outstanding
- 112.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 20, 2019
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $81.3M in FY2025.
- Revenue declined 11% from FY2020 to FY2025.
- Gross margin of 22.7%, net margin -116.7%.
- Trading 17% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Personalis, Inc..
Write a review
News about Personalis, Inc.
News & sentiment via Polygon.io
